Eli Lilly ($LLY) has posted a superior therapeutic profile for its experimental late-stage psoriasis drug ixekizumab when compared with Pfizer's ($PFE) Enbrel in a head-to-head study. It said today results were good enough for it to make a regulatory filing in the first half of 2015 for its IL-17A therapy. It is trying to get to market with new products afer generic competition has been hard on its top products. The results come just days after Novartis ($NVS) reported more positive Phase III data for its IL-17 treatment secukinumab for the same condition. Story | More